ClinicalTrials.Veeva

Menu

Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

H

Highlife Medical

Status

Enrolling

Conditions

Mitral Regurgitation

Treatments

Device: HighLife Transcatheter Mitral Valve Replacement

Study type

Interventional

Funder types

Industry

Identifiers

NCT04029363
HL-2018-01-TS Expanded EU/AU

Details and patient eligibility

About

to evaluate the safety and performance of the HighLife 28mm transcatheter, trans-septal Mitral Valve in patients with moderate-severe or severe mitral regurgitation who are at high risk for surgical treatment.

Enrollment

120 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. Age ≥ 18 years 2. Moderate-severe or severe mitral regurgitation (≥ 3+) 3. Patient has New York Heart Association (NYHA) Functional Class II, III or ambulatory IV 4. Patient is under guideline directed medical therapy, as reviewed and confirmed by the local multidisciplinary Heart Team, for at least one month 5. Patient is high-risk for open-heart surgery based on the assessment of the multidisciplinary Heart Team using standard scoring systems and consideration of co-morbidities, frailty, and disability 6. Patient meets the anatomical criteria for HighLife valve 7. Patient is willing to participate in the study and provides signed informed consent

Exclusion criteria

  1. Any stroke/TIA within 30 days

  2. Severe symptomatic carotid stenosis (> 70% by non-invasive imaging)

  3. Active infections requiring antibiotic therapy

  4. Active ulcer or gastro-intestinal bleeding in the past 3 months

  5. History of bleeding diathesis, coagulopathy or refusal of future blood transfusion

  6. Patients in whom TEE is not feasible

  7. Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months.

  8. Patient is unable to comply with the follow-up schedule and assessments

  9. Participation in another clinical investigation at the time of inclusion

  10. Patient has known allergies to the device components or contrast medium

  11. Patient cannot tolerate anticoagulation or antiplatelet therapy

  12. Patients with a life expectancy of less than 12 months due to non-cardiac conditions

  13. Patient had permanent pacemaker, or similar device with implantable cardiac leads (i.e. resynchronization therapy) within the last 3 months

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

120 participants in 1 patient group

Single arm
Other group
Description:
Single arm, non-randomized
Treatment:
Device: HighLife Transcatheter Mitral Valve Replacement

Trial contacts and locations

50

Loading...

Central trial contact

Martin Rothman, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems